Clearmind Medicine Inc. Common Shares (CMND) - Total Liabilities
Based on the latest financial reports, Clearmind Medicine Inc. Common Shares (CMND) has total liabilities worth $2.90 Million USD as of January 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Clearmind Medicine Inc. Common Shares liquidity resilience to evaluate the company's liquid asset resilience ratio.
Clearmind Medicine Inc. Common Shares - Total Liabilities Trend (2014–2025)
This chart illustrates how Clearmind Medicine Inc. Common Shares's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see CMND total assets.
Clearmind Medicine Inc. Common Shares Competitors by Total Liabilities
The table below lists competitors of Clearmind Medicine Inc. Common Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Global Power Solutions Corp.
V:PWER
|
Canada | CA$465.18K |
|
GoHealth, Inc.
NASDAQ:GOCOQ
|
USA | $1.04 Billion |
|
Alpha Compute Corp
NASDAQ:ALP
|
USA | $21.70 Million |
|
Boqii Holding Limited
NYSE:BQ
|
USA | $122.33 Million |
|
Superior Resources Ltd
AU:SPQ
|
Australia | AU$546.28K |
|
Intan Baruprana Finance Tbk
JK:IBFN
|
Indonesia | Rp1.27 Trillion |
|
InZinc Mining Ltd
V:IZN
|
Canada | CA$465.23K |
|
Alfa Financial Software Holdings PLC
LSE:ALFA
|
UK | GBX40.60 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Clearmind Medicine Inc. Common Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CMND net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Clearmind Medicine Inc. Common Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Clearmind Medicine Inc. Common Shares (2014–2025)
The table below shows the annual total liabilities of Clearmind Medicine Inc. Common Shares from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-10-31 | $4.89 Million | -15.31% |
| 2024-10-31 | $5.77 Million | +16.18% |
| 2023-10-31 | $4.97 Million | +89.48% |
| 2022-10-31 | $2.62 Million | +810.11% |
| 2021-10-31 | $288.19K | +2773.31% |
| 2020-10-31 | $10.03K | -70.37% |
| 2019-10-31 | $33.85K | +481.06% |
| 2018-10-31 | $5.83K | -88.64% |
| 2017-10-31 | $51.28K | +2.55% |
| 2016-10-31 | $50.01K | +129.78% |
| 2015-10-31 | $21.76K | -30.75% |
| 2014-10-31 | $31.43K | -- |
About Clearmind Medicine Inc. Common Shares
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It d… Read more